Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction-Reference-Cited by-同舟云学术

Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction

Published:2022-08-25 Issue:17 Volume:65 Page:11485-11496
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Inghardt Tord¹^ORCID,Antonsson Thomas¹,Ericsson Cecilia¹,Hovdal Daniel¹,Johannesson Petra¹,Johansson Carina²,Jurva Ulrik¹,Kajanus Johan¹,Kull Bengt¹,Michaëlsson Erik¹,Pettersen Anna³^ORCID,Sjögren Tove²^ORCID,Sörensen Henrik¹,Westerlund Kristina¹,Lindstedt Eva-Lotte¹

Affiliation:

1. Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, 431 50 Mölndal, Gothenburg, Sweden

2. Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, 431 50 Mölndal, Gothenburg, Sweden

3. Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, 431 50 Mölndal, Gothenburg, Sweden

Funder

AstraZeneca

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c02141